$HSTC
HST Global Inc

2020 Q1 Form 10-Q Financial Statement

#000167479620000016 Filed on May 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $34.82K $25.48K $36.31K
YoY Change -4.1% -26.4% -9.23%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $34.82K $25.48K $36.31K
YoY Change -4.1% -26.4% -9.23%
Operating Profit -$34.82K -$36.31K
YoY Change -4.1% -4.14%
Interest Expense -$20.00 $0.00 -$8.940K
YoY Change -99.78% -100.0% -10.6%
% of Operating Profit
Other Income/Expense, Net -$15.00 -$8.937K
YoY Change -99.83% 0.0%
Pretax Income -$34.83K -$25.48K -$45.25K
YoY Change -23.03% -41.49% -9.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$34.83K -$25.48K -$45.25K
YoY Change -23.03% -41.49% -9.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$10.66K -$6.945K -$18.48K
COMMON SHARES
Basic Shares Outstanding 4.248M shares 36.72M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $1.960K $0.00
YoY Change
Cash & Equivalents $0.00 $1.955K $0.00
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change
Inventory
Prepaid Expenses $0.00 $0.00
Receivables
Other Receivables
Total Short-Term Assets $0.00 $1.955K $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $0.00 $1.955K $0.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $0.00 $1.955K $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.060K $5.390K $515.4K
YoY Change -99.41% -98.94% 1.05%
Accrued Expenses $30.00K $0.00 $1.526M
YoY Change -98.03% -100.0% 11.36%
Deferred Revenue
YoY Change
Short-Term Debt $5.200K $0.00 $1.375M
YoY Change -99.62% -100.0% 1.12%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.26K $5.385K $3.416M
YoY Change -98.88% -99.84% 5.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $38.26K $5.385K $3.416M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $38.26K $5.385K $3.416M
YoY Change -98.88% -99.84% 5.44%
SHAREHOLDERS EQUITY
Retained Earnings -$5.401M -$5.366M -$5.838M
YoY Change -7.49% -7.36% 3.12%
Common Stock $4.248K $4.248K $36.72K
YoY Change -88.43% 73.53% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$38.26K -$3.430K -$3.416M
YoY Change
Total Liabilities & Shareholders Equity $0.00 $1.955K $0.00
YoY Change

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q1
OPERATING ACTIVITIES
Net Income -$34.83K -$25.48K -$45.25K
YoY Change -23.03% -41.49% -9.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.050K -$15.00K $0.00
YoY Change 233.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.090K 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.050K -15.00K 0.000
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 3.090K 0.000 0.000
Net Change In Cash -1.960K -15.00K 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$5.050K -$15.00K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2020Q1 us-gaap Assets Current
AssetsCurrent
0 usd
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1955 usd
CY2020Q1 us-gaap Assets
Assets
0 usd
CY2019Q4 us-gaap Assets
Assets
1955 usd
CY2020Q1 us-gaap Bank Overdrafts
BankOverdrafts
2113 usd
CY2019Q4 us-gaap Bank Overdrafts
BankOverdrafts
0 usd
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1571 usd
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3910 usd
CY2020Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1490 usd
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1475 usd
CY2020Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
30000 usd
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
0 usd
CY2020Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
3090 usd
CY2019Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0 usd
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
38264 usd
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5385 usd
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Entity File Number
EntityFileNumber
000-15303
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
HST Global, Inc.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
73-1215433
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
150 Research Drive
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hampton
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23666
CY2020Q1 dei City Area Code
CityAreaCode
757
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
766-6100
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4247993 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1955 usd
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2020Q1 us-gaap Liabilities
Liabilities
38264 usd
CY2019Q4 us-gaap Liabilities
Liabilities
5385 usd
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4247993 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4247993 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4247993 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4247993 shares
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
4248 usd
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4248 usd
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5358236 usd
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5358236 usd
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5400748 usd
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5365914 usd
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-38264 usd
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3430 usd
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1955 usd
CY2020Q1 us-gaap Revenues
Revenues
0 usd
CY2019Q1 us-gaap Revenues
Revenues
0 usd
CY2020Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
30000 usd
CY2019Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
30000 usd
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4818 usd
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6308 usd
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
34818 usd
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
36308 usd
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34818 usd
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36308 usd
CY2020Q1 us-gaap Interest Expense
InterestExpense
15 usd
CY2019Q1 us-gaap Interest Expense
InterestExpense
8937 usd
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15 usd
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8937 usd
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34833 usd
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45245 usd
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-34833 usd
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-45245 usd
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3268814 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2447991 shares
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-34833 usd
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-45245 usd
CY2020Q1 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
CY2019Q1 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
CY2020Q1 us-gaap Increase Decrease In Book Overdrafts
IncreaseDecreaseInBookOverdrafts
2113 usd
CY2019Q1 us-gaap Increase Decrease In Book Overdrafts
IncreaseDecreaseInBookOverdrafts
126 usd
CY2020Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
3090 usd
CY2019Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2340 usd
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6182 usd
CY2020Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
30000 usd
CY2019Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
30000 usd
CY2020Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
15 usd
CY2019Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
8937 usd
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1955 usd
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2020Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2019Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2020Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1955 usd
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
0 usd
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1955 usd
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2020Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2019Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2019Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><b>NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES </b></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">HST Global, Inc. (the "Company") was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations.  Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia.</p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnotes necessary for a complete presentation of the Company’s financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of the Company as of and for the fiscal year ended December 31, 2019. The results of operations for the period ended March 31, 2020, are not necessarily indicative of the results for a full-year period.</p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">HST Global, Inc. is an integrated Health and Wellness Biotechnology company that intends to developing and/or acquiring a network of Wellness Centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases.  In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases.</p>
CY2020Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K and 10-Q.  </p>
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and </p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

Files In Submission

Name View Source Status
0001674796-20-000016-index-headers.html Edgar Link pending
0001674796-20-000016-index.html Edgar Link pending
0001674796-20-000016.txt Edgar Link pending
0001674796-20-000016-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hstc-20200331.htm Edgar Link pending
hstc-20200331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hstc-20200331_def.xml Edgar Link unprocessable
hstc-20200331_lab.xml Edgar Link unprocessable
hstc-20200331_pre.xml Edgar Link unprocessable
hstc-20200331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
hstc-20200331_cal.xml Edgar Link unprocessable